Low dose 1-hexylcarbamoyl-5-fluorouracil (HCFU) recommended for cirrhotic patients with hepatocellular carcinoma

This publication has 11 references indexed in Scilit:

• 1-hexylcarbamoyl-5-fluorouracil is more cytostatic than 5-fluorouracil against human tumors in vitro
  European Journal of Cancer and Clinical Oncology, 1987
• Reversible leukoencephalopathy caused by 5-fluorouracil derivatives, presenting as akinetic mutism
  Surgical Neurology, 1986
• Neuropathologic study on chronic neurotoxicity of 5-fluorouracil and its masked compounds in dogs
  Acta Neuropathologica, 1984
• Identification of minor metabolites of 5-fluorocytosine in man by chemical ionization gas chromatography mass spectrometry
  Journal of Mass Spectrometry, 1981
• “Organic brain syndrome” secondary to 5-fluorouracil toxicity
  Diseases of the Colon & Rectum, 1981
• Distribution of 1-hexylcarbamoyl-5-fluorouracil and 5-fluorouracil by oral administration in mice.
  Journal of Pharmacobio-Dynamics, 1979
• Plasma amino acid quantitation using gas chromatography chemical ionization mass spectrometry and13C amino acids as internal standards
  Journal of Mass Spectrometry, 1978
• LOCALIZED CHANGES IN BLOOD-BRAIN-BARRIER PERMEABILITY FOLLOWING ADMINISTRATION OF ANTI-NEOPLASTIC DRUGS
  1978
• Metabolic Fate of 1-Hexylcarbamoyl-5-fluorouracil in Rats
  Xenobiotica, 1978
• Neurotoxicity of Commonly Used Antineoplastic Agents
  New England Journal of Medicine, 1974